This is a working overview of nitric oxide system, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-23. Anything still debated is marked as such rather than presented as settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Refers to trials to find better ways to prevent disease in people who have never had the disease or to prevent a disease from returning. These approaches may include medicines, vaccines, vitamins, minerals, or lifestyle changes. (NLM) Preventive
=== Iberia === Vocabvlario da Lingoa de Iapam, a Japanese-Portuguese dictionary, was compiled and published in 1603 by Jesuit priests in Nagasaki. It contains short but clear definitions for about 20 words related to soyfoods—the first in any European language. The Luso-Hispanic traders were familiar with soybeans and soybean product through their trade with Far East since at least the 17th century. However, it was not until the late 19th century that the first attempt to cultivate soybeans in the Iberian peninsula was undertaken. In 1880, the soybean was first cultivated in Portugal in the Botanical Gardens at Coimbra (Crespi 1935). In about 1910 in Spain the first attempts at Soybean cultivation were made by the Count of San Bernardo, who cultivated soybeans on his estates at Almillo (in southwest Spain) about 48 miles east-northeast of Seville.
=== Labia === The large outer pair of folds are the labia majora, which contain and protect the labia minora and other structures of the vulva. The labia majora meet at the front of the mons pubis, and meet posteriorly at the urogenital triangle (the anterior part of the perineum) below the anus. The labia minora are the small inner pair of skin folds that protect the openings. The labia minora are often pink or brownish black, relevant to the person's skin color. The grooves between the labia majora and minora are called the interlabial sulci, or interlabial folds. The labia minora meet posteriorly as the frenulum (fourchette).
== Legacy == Following the dissolution of the Selous Scouts in 1980, most of its white soldiers emigrated to South Africa and were integrated into the South African Special Forces and the South African Police's special units. This formed part of an effort by the SADF to recruit white veterans of Rhodesian counter-insurgency units that was designated Operation Winter. Reid-Daly was among the Selous Scouts who moved to South Africa, and was appointed the head of Transkei Defence Force (the military of the nominally independent 'bantustan' of Transkei) in the early 1980s. He recruited other former Selous Scouts to train the force, but was forced to resign in 1987 after Transkei's rulers were overthrown by a military officer who had previously been trained by the Selous Scouts. The former Selous Scouts contributed to the adoption by the South African security forces of the unit's ruthless tactics. For instance, former Selous Scouts comprised most of the initial personnel of the South African Koevoet unit, and it used similar tactics. This unit was responsible for many human rights violations. The South African Police's Vlakplaas paramilitary hit squad that was established in 1979 was also inspired by the Selous Scouts, as was the Civil Cooperation Bureau that was formed in 1986. Following the end of the Apartheid regime in South Africa some former Selous Scouts joined private military companies. Reid-Daly's memoirs Selous Scouts: Top Secret War, which were first published in 1982, have had a strong influence on the historiography of the Rhodesian Bush War.
Se + O2 → SeO2 It is a polymeric solid that forms monomeric SeO2 molecules in the gas phase. It dissolves in water to form selenous acid, H2SeO3. Selenous acid can also be made directly by oxidizing elemental selenium with nitric acid:
Sources: en.wikipedia.org
== Prescription labels == Medication packaging includes a document that provides information about that drug and its use. In the US, this information is overseen by the Center for Drug Research and Evaluation (CDER), a branch of the Food and Drug Administration (FDA). For prescription medications, the insert is technical, and provides information for medical professionals about how to prescribe the drug. Package inserts for prescription drugs often include a separate document called a "patient package insert" with information written in plain language intended for the end-user -- the person who will take the drug or administer the drug to another person. Inserts for over-the-counter medications are also written plainly. In the US the document is called "prescribing information" or the "package insert" (PI) and layperson's document is called the "patient package insert" (PPI). In Europe the technical document is called the "summary of product characteristics" and the document for end-users is called the "package leaflet". The bottle or box also has information printed on it, intended for the person taking the medication.
=== Vacuum systems === SSIMS experiments are performed in high vacuum for two reasons: first, to avoid scattering of the primary and secondary beams, and second, to prevent interfering adsorption of gases (i.e. oxygen) on the surface under investigation. For the first requirement, a pressure lower than 10−5 mbar is sufficient to ensure a mean free path that is long compared with the beam path. One monolayer of gas forms in 1 second at a pressure of 10−6 mbar. Thus for SSIMS analyses a pressure of ~ 10−10 mbar is needed to allow adequate time to complete the experiment.
== Commercialization == Since the first publication by Kansy and coworkers, several companies developed their own versions of the assay. Early models incorporated iso-pH conditions in the compartments separated by a simple lipid membrane; subsequently, commercial products were introduced which incorporated more sophisticated lipid membranes. The commercial products helped ensure that medicinal chemists across different corporate labs within a worldwide organization used the same standardized methodology, reagents and obtained equivalent system performance as demonstrated with a set of test compounds. This has proved very useful as various operational activities have been outsourced to other countries.
Strontium is named after the Scottish village of Strontian (Scottish Gaelic: Sròn an t-Sìthein), where it was discovered in the ores of the lead mines. In 1790, Adair Crawford, a physician engaged in the preparation of barium, and his colleague William Cruickshank, recognised that the Strontian ores exhibited properties that differed from those in other "heavy spars" sources. This allowed Crawford to conclude on page 355 "... it is probable indeed, that the scotch mineral is a new species of earth which has not hitherto been sufficiently examined." The physician and mineral collector Friedrich Gabriel Sulzer analysed together with Johann Friedrich Blumenbach the mineral from Strontian and named it strontianite. He also came to the conclusion that it was distinct from the witherite and contained a new earth (neue Grunderde). In 1793 Thomas Charles Hope, a professor of chemistry at the University of Glasgow studied the mineral and proposed the name strontites. He confirmed the earlier work of Crawford and recounted: "... Considering it a peculiar earth I thought it necessary to give it an name. I have called it Strontites, from the place it was found; a mode of derivation in my opinion, fully as proper as any quality it may possess, which is the present fashion." The element was eventually isolated by Sir Humphry Davy in 1808 by the electrolysis of a mixture containing strontium chloride and mercuric oxide, and announced by him in a lecture to the Royal Society on 30 June 1808. In keeping with the naming of the other alkaline earths, he changed the name to strontium.
=== Mast cell activation biomarkers === Mast cell activation occurs when stimuli trigger the release of chemical mediators by mast cells. A wide variety of mediators can be released. Biomarkers for detecting mast cell activation fall into two classes, depending on how they can be detected. Some mediators may be measurable as circulating molecules in biological fluids such as blood or urine. Other cell surface markers may need to be isolated from tissues to be measured, using flow cytometry. The most generally accepted biomarker for detecting mast cell activation is the measurement of tryptase. Levels during a symptomatic episode should ideally be compared to a baseline. Serum tryptase levels can be difficult to obtain and compare. Newer diagnostic tools include the measurement of mast cell mediators in urine. Such mediators can be more easily obtained during symptoms and at baseline. Mediators that are unstable molecules (e.g. histamine, cysteinyl leukotrienes, and prostaglandin D2) are difficult to use as biomarkers. Surface markers which bind to receptors on the MC surface include FcεRI, CD117, CD63, CD69, CD203c, and CD107a/b. They can be detected by flow cytometry and some may be used for the detection of cells in mastocytosis. However, they have not been validated as biomarkers of MC activation. It may be difficult to differentiate adult mast cells and stem or progenitor cells because both express markers like CD117 and FcεRI.
Sources: en.wikipedia.org
Therefore, hyperhomocysteinemia is a possible risk factor for coronary artery disease. Coronary artery disease occurs when an atherosclerotic plaque blocks blood flow to the coronary arteries, which supply the heart with oxygenated blood. Hyperhomocysteinemia has also been correlated with the occurrence of blood clots, heart attacks, and strokes, although it is unclear whether hyperhomocysteinemia is an independent risk factor for these conditions. Hyperhomocysteinemia has also been associated with early-term spontaneous abortions and with neural tube defects.
=== Federal dissolution; the roots of mistrust === Meanwhile, secessionist black Rhodesian parties won electoral victories in Northern Rhodesia and Nyasaland, and Harold Macmillan's Conservative administration in Britain moved towards breaking up the Federation, resolving that it had become untenable. In February 1962, the British Secretary of State for Commonwealth Relations, Duncan Sandys, secretly informed the Nyasaland nationalist leader Hastings Banda that secession would be allowed. A few days later, he horrified Welensky by telling him that "we British have lost the will to govern". "But we haven't", retorted Julian Greenfield, Welensky's Law Minister. Macmillan's Deputy Prime Minister and First Secretary of State, R. A. Butler, who headed British oversight of the Federation, officially announced Nyasaland's right to secede in December 1962. Four months later, he informed the three territories that he was going to convene a conference to decide the Federation's future. As Southern Rhodesia had been the UK's legislative partner in forming the Federation in 1953, it would be impossible (or at least very difficult) for Britain to dissolve the union without Southern Rhodesia's co-operation. Field could therefore potentially hamstring the British by refusing to attend the conference until they pledged to grant his country full independence. According to Field, Smith and other RF politicians, Butler made several such guarantees orally to ensure their co-operation at the conference, but repeatedly refused to give anything on paper.
=== Traditional medicine === Xanthoria parietina has a long history of use in traditional medicine across several cultures. In Andalucia, Spain, this lichen was known as flor de piedra ('stone flower') or rompepiedra ('stone breaker'). Spanish traditional healers employed it for several purposes: treating menstrual complaints when prepared as a decoction in wine, addressing kidney disorders and toothaches when made into water-based decoctions, and serving as a general analgesic. They also incorporated it into cough syrups along with various plant ingredients. In European traditional medicine during the early modern era, X. parietina was boiled with milk to treat jaundice, often alongside Polycauliona candelaria. This application exemplifies the Doctrine of signatures – a belief system that plants resembling parts of the body could treat ailments of those parts – as the yellow-orange color of the lichen was thought to indicate its efficacy against the yellowing of the skin in jaundice. In Traditional Chinese medicine, it was known as Chinese: shí huáng yī ('stone yellow clothes') and valued for its antibacterial properties. The widespread medicinal use of lichens, including X. parietina, had been mostly abandoned by 1800, and these applications represent historical folk remedies rather than evidence-based treatments.
==== New Zealand ==== Since April 2024, pseudoephedrine has been classified as a restricted (pharmacist-only) drug in the Misuse of Drugs Act 1975 which allows the purchase of medicines containing pseudoephedrine from a pharmacist without a prescription. Pseudoephedrine, ephedrine, and any product containing these substances, e.g. cold and flu medicines, were first classified in October 2004 as Class C Part III (partially exempted) controlled drugs, due to being the principal ingredient in methamphetamine. New Zealand Customs and police officers continued to make large interceptions of precursor substances believed to be destined for methamphetamine production. On 9 October 2009, Prime Minister John Key announced pseudoephedrine-based cold and flu tablets would become prescription-only drugs and reclassified as a class B2 drug. The law was amended by The Misuse of Drugs Amendment Bill 2010, which passed in August 2011. In November 2023, the National-led coalition government announced that the sale of cold medication containing pseudoephedrine would be allowed (as part of the coalition agreement between the National and ACT parties).
=== Physical === Most of the physical properties of astatine have been estimated (by interpolation or extrapolation), using theoretically or empirically derived methods. For example, halogens get darker with increasing atomic weight—fluorine is nearly colorless, chlorine is yellow-green, bromine is red-brown, and iodine is dark gray/violet. Astatine is sometimes described as probably being a black solid (assuming it follows this trend), or as having a metallic appearance (if it is a metalloid or a metal). Because it has a lower vapor pressure than iodine, astatine sublimes, as expected. Half of a given quantity of astatine will vaporize in approximately an hour if put on a clean glass surface at room temperature. The absorption spectrum of astatine in the middle ultraviolet region has lines at 224.401 and 216.225 nm, suggestive of 6p to 7s transitions. The structure of solid astatine is unknown. As an analog of iodine it may have an orthorhombic crystalline structure composed of diatomic astatine molecules, and be a semiconductor (with a band gap of 0.7 eV). Alternatively, if condensed astatine forms a metallic phase, as has been predicted, it may have a monatomic face-centered cubic structure; in this structure, it may well be a superconductor, like the similar high-pressure phase of iodine. Metallic astatine is expected to have a density of 8.91–8.95 g/cm3. Evidence for (or against) the existence of diatomic astatine (At2) is sparse and inconclusive.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.